Reference

Drug

Design

No Patients

 Time  Follow-Up

  End Point Results

Hausleiter J et al. [7]

Sirolimus

(3 arms)
BMS + placebo vs. BMS + usual-dose sirolimus vs. BMS + high-dose sirolimus

300

12 months

Positive(angiographic)

Cernigliaro C et al. [9]

Sirolimus

(2 arms)
BMS + placebo vs. BMS + sirolimus

108

60 months

Positive(angiographic)

Rodriguez AE et al. [8]

Sirolimus

(2 arms)
BMS + sirolimus vs. BMS

100

9 months

Positive(angiographic)

Stojkovic S et al. [10]

Sirolimus

BMS + sirolimus vs. BMS

80

6 months

Positive(angiographic)

Rodriguez AE et al. [14]

Sirolimus

(2 arms)
BMS + sirolimus vs. DES

200

    36 months

Positive (cost-effectiveness)

Versaci F et al. [11]

Prednisone

(2 arms)
BMS

83

12 months

Positive(clinical)

Ribichini F et al. [13]

Prednisone

(3 arms)
BMS vs. BMS + prednisone vs. DES

375

12 months

Positive(clinical)

BMS: Bare Metal Stents; DES: Drug Eluting Stents

Table 1: Randomized Clinical Trials assessing Oral Immunosuppressive Therapies for the Treatment of Restenosis in Coronary Artery Disease.